Leukemia Research

Leukemia Research is a monthly Elsevier title founded in 1977 that publishes basic and clinical work on hematological malignancies. It is the official journal of The Myelodysplastic Syndromes Foundation. Its 2025 Journal Impact Factor is 2.4 and its CiteScore is 4.1.《白血病研究》是 Elsevier 出版的月刊，1977 年创刊，刊载血液肿瘤的基础与临床研究，现为 The Myelodysplastic Syndromes Foundation 的官方期刊。其 2025 年期刊影响因子为 2.4，CiteScore 为 4.1。

Scope

• The stated aim is to give every health professional engaged in basic or clinical work on hematological malignancies comprehensive and timely information.该刊声明的宗旨，是向所有从事血液肿瘤基础或临床工作的卫生专业人员提供全面而及时的信息。

• Six areas are named in the scope statement, namely cell and molecular biology, genetics, immunology, epidemiology, clinical evaluation and treatment.范围说明列出六个方向，即细胞与分子生物学、遗传学、免疫学、流行病学、临床评价与治疗。

• Cell and molecular biology heads the list, and it takes in the mechanisms through which leukemic clones arise, expand and escape treatment.细胞与分子生物学排在首位，涵盖白血病克隆如何产生、扩增并逃逸治疗的机制。

• Genetics follows, covering the cytogenetic lesions and the mutation profiles that now sort acute leukemia into risk groups.遗传学紧随其后，涉及细胞遗传学异常与突变图谱，急性白血病如今正靠这些指标划分风险组。

• Immunology covers the immune phenotype of these diseases and the immune-based treatments that have grown out of it.免疫学覆盖这类疾病的免疫表型，也覆盖由此发展起来的免疫治疗。

• Epidemiology brings in incidence, risk factors and outcome patterns at the level of whole populations.流行病学纳入人群层面的发病率、危险因素与转归格局。

• Clinical evaluation takes in diagnosis, prognostic scoring and trial design, while treatment covers chemotherapy, transplantation and targeted agents.临床评价涉及诊断、预后评分与试验设计，治疗部分则涉及化疗、移植与靶向药物。

• Original articles stop at 4,000 words, carry an abstract of 250 words, cite no more than 50 references and keep figures and tables to six in all.原创论文以 4000 词为限，摘要 250 词，参考文献不超过 50 条，图与表合计不超过 6 个。

• Reviews may run to 5,000 words with as many as 150 references, and no ceiling is placed on figures and tables.综述可达 5000 词，参考文献最多 150 条，图表数量不设上限。

• Correspondence is held to 1,500 words outside the reference list, with two display items and 20 references at most.通讯限 1500 词（不计参考文献），图表最多 2 个，参考文献最多 20 条。

• Commentary is written by invitation, runs to 1,500 words and comes with ten references, one figure and one table.评论由编辑部约稿，篇幅 1500 词，配 10 条参考文献与 1 幅图、1 张表。

• An open access companion title appears under a title of its own. The pair are companion titles rather than a parent journal and a subsidiary.另有一份开放获取的姊妹刊，以独立刊名出版。两者是并列的姊妹刊，没有主刊与子刊之分。

History

• The first volume appeared in 1977 under the Pergamon Press imprint, with Oxford and New York named as the places of publication.第 1 卷于 1977 年在 Pergamon Press 名下问世，出版地标注为牛津与纽约。

• Volume 31 belongs to 2007, which fixes volume 1 in 1977 and shows that the numbering has never been restarted.第 31 卷对应 2007 年，由此可定第 1 卷为 1977 年，卷号从未重新起算。

• A single volume covered each year from 2007 to 2015, so volume 32 is 2008 and volume 39 is 2015.2007 年至 2015 年每年一卷，第 32 卷即 2008 年，第 39 卷即 2015 年。

• The arrangement changed in 2016. From volume 40 onward, each monthly issue has been bound as a volume of its own.这一安排在 2016 年改变。自第 40 卷起，每一期月刊各自成为一卷。

• Volumes 40 to 51 therefore cover 2016, and the sequence has run at twelve volumes a year ever since.第 40 至 51 卷因此对应 2016 年，此后每年十二卷的节奏一直延续。

• 2026 falls across volumes 160 to 171, and volume 171, dated December, is still being assembled.2026 年横跨第 160 卷到第 171 卷，标注 12 月的第 171 卷仍在组稿。

• Elsevier is the publisher of record today, and the footer of the journal site reads Copyright 2026 Elsevier Ltd. The imprint had passed from Pergamon Press by the time the current volumes appeared.如今登记的出版方是 Elsevier，期刊网站页脚标注 Copyright 2026 Elsevier Ltd。现名下的各卷问世时，出版权早已从 Pergamon Press 转到 Elsevier 手中。

• The print number is 0145-2126 and the electronic number 1873-5835.印本刊号为 0145-2126，电子刊号为 1873-5835。

• The tie with The Myelodysplastic Syndromes Foundation brought the foundation's congress abstracts into the journal, and such supplements are now a regular part of the output.与 The Myelodysplastic Syndromes Foundation 的关系把该基金会大会的摘要带进刊物，这类增刊如今已是固定内容。

• MEDLINE has indexed it from volume 3, number 1, in 1979, and Index Medicus carried it from the same point.MEDLINE 自 1979 年第 3 卷第 1 期起收录该刊，Index Medicus 也从同一时间开始著录。

• Publication follows a hybrid model. Subscribers pay for access, authors may choose open access, and 21.91 per cent of the content is gold open access.出版采用混合模式。订阅者为阅读付费，作者可选择开放获取，金色开放获取占全部内容的 21.91%。

• The 2025 Journal Impact Factor is 2.4 and the five-year figure is 2.5, while CiteScore stands at 4.1.2025 年期刊影响因子为 2.4，五年影响因子为 2.5，CiteScore 为 4.1。

• Journal Citation Reports place it 51st of 103 in Hematology, the second quartile, and 214th of 333 in Oncology, the third.Journal Citation Reports 把该刊排在血液学 103 种期刊中的第 51 位，属第二四分位，在肿瘤学 333 种期刊中排第 214 位，属第三四分位。

• Its Journal Citation Indicator is 0.52 at the 51st percentile, citations total 4,850 against 70 articles a year, and the cited half-life is 11.3 years.期刊引文指标为 0.52，百分位 51，总被引 4850 次，年发文 70 篇，被引半衰期 11.3 年。

• Abstracts from the 17th international congress of the foundation were published in 2023, and the 18th congress, held in Rotterdam in May 2025, followed the same route.基金会第 17 届国际大会的摘要于 2023 年刊出，2025 年 5 月在鹿特丹举行的第 18 届沿用这一做法。

• A supplement gathered papers from a symposium on non-Hodgkin lymphoma in children and adolescents. Adult T-cell leukemia lymphoma received a special issue of its own, with (Kunihiro Tsukasaki) as guest editor.一份增刊汇集了儿童与青少年非霍奇金淋巴瘤研讨会的论文。成人 T 细胞白血病淋巴瘤另有专属专题，由（Kunihiro Tsukasaki）担任客座编辑。

Editors

• Two editors in chief share the chair. Julie Anne Elizabeth Irving works at Newcastle University in Newcastle upon Tyne, United Kingdom.主编一职由两位学者共同担任。其中（Julie Anne Elizabeth Irving）任职于英国泰恩河畔纽卡斯尔的 Newcastle University。

• The other editor in chief, Lukas Frenzel, works at the University of Cologne in Germany.另一位主编（Lukas Frenzel）任职于德国 University of Cologne。

• Two associate editors complete the handling team. (Luis F. Porrata) works at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota.负责审理的团队另有两位副编辑。（Luis F. Porrata）任职于明尼苏达州罗切斯特的 Mayo Foundation for Medical Education and Research。

• The second is (Daniel Thomas) of the Adelaide University School of Medicine in Australia.另一位是（Daniel Thomas），任职于澳大利亚的 Adelaide University School of Medicine。

• Forty-nine people sit on the editorial board, and the site counts 52 editors and board members from 18 countries and territories.编委会由 49 人组成，官网统计的编辑与编委共 52 位，来自 18 个国家或地区。

• The United States supplies 18 of them, Australia four and Italy four.其中美国 18 人，澳大利亚 4 人，意大利 4 人。

• Among the American members are (Ronald Hoffman) of the Icahn School of Medicine at Mount Sinai, (Shimin Hu) of MD Anderson and (Bruno Medeiros) of Stanford University.美国成员中有 Icahn School of Medicine at Mount Sinai 的（Ronald Hoffman）、MD Anderson 的（Shimin Hu）与 Stanford University 的（Bruno Medeiros）。

• Europe holds (Peter A. Valent) at the Medical University of Vienna, (Laurence de Leval) at Lausanne University Hospital and (Marek Mraz) at Masaryk University in Brno.欧洲的席位由三位学者出任，分别是 Medical University of Vienna 的（Peter A. Valent）、Lausanne University Hospital 的（Laurence de Leval）与布尔诺 Masaryk University 的（Marek Mraz）。

• The board also reaches Asia. (Qian Jiang) and (Junling Zhuang) both work in Beijing, at the Peking University People's Hospital and the Peking Union Medical College Hospital respectively.编委也延伸到亚洲。（Qian Jiang）与（Junling Zhuang）都在北京工作，分别任职于 Peking University People's Hospital 与 Peking Union Medical College Hospital。

• (Lanzhu Yue) works at Tianjin Medical University and (Supeng Yeh) at the China Medical University Hospital in Taiwan.（Lanzhu Yue）任职于天津医科大学，（Supeng Yeh）任职于台湾的中国医药大学附设医院。

• Elsewhere the list carries (Anthony Oyekunle) at Te Whatu Ora in New Zealand, (Alberto Almeida) at the Pontificia Universidad Catolica de Chile and (Agnes Yong) at the South Australian Health and Medical Research Institute.其余成员包括新西兰 Te Whatu Ora 的（Anthony Oyekunle）、智利 Pontificia Universidad Catolica de Chile 的（Alberto Almeida），以及 South Australian Health and Medical Research Institute 的（Agnes Yong）。

• Peer review is single anonymized, and at least two reviewers report on each manuscript.评审采用单匿名方式（single anonymized review process），每篇稿件至少由两位审稿人出具意见。

• Editors step aside from manuscripts written by relatives or close colleagues, and such papers go to another editor.编辑不处理本人亲属或同事撰写的稿件，这类稿件改由其他编辑独立处理。

• Each manuscript carries one appeal only.每篇稿件只受理一次申诉。

• Papers enter through Editorial Manager. The journal reports 17 days from submission to first decision, 48 days from review to decision, 101 days to acceptance and 2 days from acceptance to online publication.稿件经 Editorial Manager 投递。该刊公布的时间为投稿到首次决定 17 天，送审到决定 48 天，投稿到接收 101 天，接收到上线 2 天。